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Abstract
Background: A C825T polymorphism was recently identified in the gene encoding the β3 subunit
of heterotrimeric G-proteins (GNB3). The T-allele is significantly associated with essential
hypertension and obesity. In order to further explore a possible pathogenetic link between the T-
allele and impaired glucose tolerance we studied metabolic and haemodynamic responses to oral
glucose loading in young, healthy subjects with and without the 825T-allele.
Methods: Twelve subjects with and 10 without the 825T-allele were investigated at rest and
following glucose ingestion (75 g). Blood glucose, serum insulin and haemodynamics were
determined prior to and over 2 hours following glucose ingestion. We non-invasively measured
stroke volume (SV, by impedance-cardiography), blood pressure (BP), heart rate (HR), and systolic-
time-intervals. Cardiac output (CO) was calculated from HR and SV. Total peripheral resistance
was calculated from CO and BP. Metabolic and haemodynamic changes were quantified by maximal
responses and by calculation of areas under the concentration time profile (AUC). Significances of
differences between subjects with and without the T-allele were determined by unpaired two-tailed
t-tests. A p < 0.05 was considered statistically significant.
Results: Metabolic and haemodynamic parameters at baseline were very similar between both
groups. The presence of the T-allele did not alter the response of any metabolic or haemodynamic
parameter to glucose loading.
Conclusions:  In conclusion, this study does not support the hypothesis that the C825T
polymorphism may serve as a genetic marker of early impaired glucose tolerance.
Background
The pathogenesis of hypertension is characterized by a
strong genetic background [1]. Recently a C825T poly-
morphism was identified in the gene GNB3  which
encodes the β3 subunit of heterotrimeric G proteins and
an association of the T-allele of this polymorphism with
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hypertension has been demonstrated [2]. The prevalence
of the 825T-allele was found to be significantly increased
in middle-European Caucasian subjects with essential
hypertension, with an odds ratio for homozygous 825T-
allele carriers of approximately 1.8 [2]. Association of the
825T-allele with hypertension has been confirmed in four
additional independent patient samples, i.e. a popula-
tion-based, cross-sectional study from southern Germany
[3], a group of patients with established essential hyper-
tension from a German hypertension clinic [4], a cohort
of white Australian hypertensives with a strong family
background of essential hypertension [5] and in a popu-
lation-based sample of black people of African origin [6].
The mechanisms linking the presence of the T-allele to the
development of hypertension in later life are, however,
unclear. Interestingly, the T-allele is not only associated
with hypertension but a consistent association with obes-
ity has also been shown in different and independent
samples both in subjects with normal blood pressure [7]
and in hypertensive patients [8].
It has long been recognized that both hypertension and
obesity are associated with impaired insulin resistance
and glucose intolerance [9,10]. However, it is a matter of
ongoing debate, whether this disturbance of glucose
metabolism contributes pathogenetically to the develop-
ment of enhanced total peripheral resistance as the
haemodynamic hallmark of hypertension or whether,
vice versa, impaired glucose tolerance is a mere conse-
quence of the haemodynamic changes that take place dur-
ing the development of hypertension [11,12].
If impaired glucose tolerance is a contributory cause and
not only a sequelae of hypertension we hypothesized that
young, normotensive men who differed only with respect
to genotype at the GNB3 locus, i.e. with respect to their
genetic predisposition to develop hypertension should be
characterized by impaired glucose tolerance. In order to
further explore a possible pathogenetic link between the
C825T polymorphism and impaired glucose tolerance we
have therefore compared blood glucose and serum insulin
responses following an oral glucose load in young,
healthy, normotensive, non-obese men with and without
the 825T-allele. In order to assess the possible contribu-
tion of haemodynamic alterations we also non-invasively
measured haemodynamics at rest and in response to oral
glucose loading.
Methods
Study Population and Protocol
The study was performed in 22 young, male volunteers
after informed, written consent had been obtained. All
subjects were drug free and judged to be healthy on the
basis of medical history, physical examination, electrocar-
diogram and routine laboratory screening. Routine labo-
ratory screening included measurements of serum
electrolytes, white and red blood cell count, thrombocyte
count, hemoglobin, hematocrit, fasting glucose, choles-
terol, uric acid, creatinine, urea, lactate dehydrogenase,
bilirubin, gamma glutamyl transpeptidase, glutamic pyru-
vic transaminase, thromboplastin time, and partial
thromboplastin time. Subjects and investigators were
blinded with regard to genotype at the GNB3 locus. The
study protocol had been approved by the Ethics Commit-
tee of the University of Essen Medical School and was in
accordance with the principles laid down in the Declara-
tion of Helsinki.
12 subjects were carriers of the 825T-allele (9 hetero- and
3 homozygous), while 10 subjects without this allele
served as controls. On the study day, subjects were
reported to the laboratory at 7–8 a.m. after an overnight
fast and remained in the supine position during the entire
investigation. One indwelling catheter was placed into an
antecubital forearm vein, which was used for blood with-
drawals. Each subject was instrumented with a blood pres-
sure cuff, circular tape electrodes for measurement of
transthoracic impedance and a microphone for phonocar-
diographic recordings.
After a resting period of 30 min, baseline haemodynamic
measurements were performed and blood for baseline
measurements of whole blood glucose and serum insulin
was taken. Thereafter, each subject drank a standardized
commercially available solution containing 75 g of glu-
cose (Dextro®  O.G.T., Boehringer Mannheim, Milano,
Italy) over five minutes. Fifteen, 30, 60, 90 and 120 min-
utes min after intake of the glucose solution haemody-
namic measurements were repeated and blood was drawn
for determination of blood glucose and serum insulin.
Biochemical, Anthropometric and Haemodynamic 
Measurements
Whole blood glucose was determined by the glucose oxi-
dase method (glucose autoanalyser, EBIO 6666, Eppen-
dorf, Hamburg, Germany). Serum insulin levels were
assessed by radioimmunoassay (Biochem Immunosys-
tems, Freiburg, Germany).
Height and weight were measured and body mass index
(BMI) was calculated as weight to height squared. Systolic
(SBP) and diastolic blood pressure (DBP) [mm Hg] was
measured with a standard mercury sphygmomanometer
with the disappearance of Korotkow's sound defined as
diastolic blood pressure (DBP).
We measured systolic time intervals (STI) to characterize
left ventricular performance. Systolic time intervals pro-
vide an accurate and sensitive measure of left ventricular
function [13,14]. STI were measured according toCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/7
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standard techniques [13,15] from simultaneous record-
ings of an electrocardiographic lead, a phonocardiogram
and a carotid pulse tracing at high paper speed (100 mm
× s-1) using a Siemens-Cardirex®  multichannel ink jet
recorder (Siemens Medizintechnik, Erlangen, Germany)
as previously described [16–19]. From these recordings
we determined the duration of the RR-interval to calculate
heart rate (HR) [b.p.m.] and the duration of the electro-
mechanical systole which was corrected for heart rate to
yield QS2c [20].
Stroke volume (SV) [ml] was measured by impedance car-
diography using the standard approach with circular tape
electrodes and graphical signal analysis according to
Kubicek's equation [21,22]. A 'Kardio-Dynagraph' was
used to record changes in transthoracic impedance (Heinz
Diefenbach Elektromedizin, Frankfurt, Germany). Imped-
ance cardiography yields measurements that agree closely
with those obtained by Doppler echocardiography or
thermodilution [23], and is acceptable for clinical use par-
ticularly in studies investigating young subjects free from
any cardiovascular disease [24]. In our laboratory, we
have determined that the variability of stroke volume
measured by impedance cardiography is less than 5.5 %
(expressed as a percentage of the coefficient of variation)
[18].
Cardiac output (CO) [l × min-1] was calculated as CO =
HR × SV /1000. Total peripheral resistance (TPR) [dyne ×
sec × cm-5] was calculated as mean arterial pressure × 80
divided by CO, where mean arterial pressure was defined
as DBP plus one third of pulse pressure. Pulse pressure
was calculated by subtracting DBP from SBP.
Insulin Sensitivity and Statistical Analysis
The following indices of glucose tolerance or insulin sen-
sitivity, respectively, were evaluated: i) fasting insulin lev-
els, ii) relative insulin resistance expressed by the
homeostatic model assessment HOMA IR (fasting insulin
(µU dl-1) × fasting glucose (mg dl-1)/22.5) [25], iii) the
maximum change in insulin and glucose from baseline
following oral glucose loading, iv) the area under the
insulin response profile (AUC) as a marker of total insulin
secretion, and v) the insulinogenic index as a marker of
early phase insulin secretion [26]. The insulinogenic
index was measured as ratio of increment of insulin to
that of glucose at 30 minutes after glucose ingestion [26].
The metabolic and haemodynamic response to oral glu-
cose loading was described by the changes from fasting
baseline values. Maximum change and area under the
response profile (AUC) following glucose loading were
determined for all parameters.
Based on population studies [2–4,6,27], our primary
hypothesis was that the presence of the T-allele
(homozygous or heterozygous) would affect metabolic
and cardiovascular function relative to homozygous C-
allele carriers. Therefore, our primary statistical compari-
sons have determined the significance of differences
between T-allele carriers and non-carriers by unpaired,
two-tailed t-tests, i.e. CT and TT subjects were pooled for
analyses. This was also necessary for epidemiological rea-
Table 1: Study population: Demographic characteristics, metabolic and haemodynamic parameters at rest.
CC CT/TT P-value 95% CI
Age [years] 25.8 ± 1.1 26.3 ± 0.6 0.711 -2.9/2.0
Height [cm] 181.7 ± 2 186.7 ± 2 0.121 -11.4/1.4
Weight [kg] 78. 2 ± 2 79.2 ± 2.5 0.783 -8.4/6.4
Body mass index [kg m-2] 23.7 ± 0.6 22.7 ± 0.4 0.174 -0.5/2.5
Fasting blood glucose [mg dl-1] 86.8 ± 2.3 86.8 ± 1.5 0.991 -5.5/5.5
Fasting serum insulin [µU dl-1] 10.4 ± 2.8 7.2 ± 1.4 0.287 -2.9/9.3
Relative insulin resistance HOMA IR 30.4 ± 5.6 28.0 ± 5.4 0.766 -18.9/14.2
Heart rate [per min] 62.5 ± 2.7 57.1 ± 2.7 0.175 -2.6/13.4
Systolic blood pressure [mm Hg] 116.9 ± 2.7 118.6 ± 1.9 0.597 -8.4/4.9
Diastolic blood pressure [mm Hg] 75.3 ± 1.9 73.7 ± 2.4 0.632 -5.1/8.2
Stroke volume [ml] 89.5 ± 8.2 107.1 ± 5.6 0.083 -37.7/2.5
Cardiac output [l min-1] 5.6 ± 0.5 6.1 ± 0.4 0.441 -1.8/0.8
Total peripheral resistance [dyne sec cm-5] 1383 ± 122.4 1216 ± 77.3 0.249 -125/458
Total electromechanical systole [ms] 480.9 ± 6.1 489.4 ± 5.4 0.306 -25.5/8.4
Number of subjects 10 12
Data are mean ± SEM. Parameters were determined in the supine position at the end of a resting period of 30 minutes. P-values were determined 
in a two-tailed unpaired t-test between CC-genotypes (data column 1) and combined CT/TT-genotypes (data column 2). 95% CI: 95% confidence 
interval. (* P < 0.05).Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/7
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sons, since only about 10% of young, German males are
homozygous T-allele carriers [28]. The number of subjects
in this study (n = 22) was within the range found in the
literature (Grossmann et al. n = 26 [29]; Wenzel el al. n =
25 [30]; Virchow et al. n = 20 [31]).
A P < 0.05 was considered statistically significant. All val-
ues are shown as mean ± SEM. 95% confidence intervals
(CI) are provided for better assessment of the precision of
group comparisons.
Results
Subjects were matched for anthropometric measures
(Table 1). Blood glucose, serum insulin, relative insulin
resistance (HOMA IR), and haemodynamic parameters at
baseline were also very similar between carriers and non-
carriers of the 825T-allele (Table 1).
The rise in glucose and insulin after oral glucose loading
was not different between 825T-allele carriers (T) and
control (C) subjects and there was no significant differ-
ence in any of the determined indices of insulin sensitivity
(Table 2, Figure 1). Oral glucose loading produced pro-
found haemodynamic changes characterized by an
increase in HR, systolic blood pressure and CO, a fall in
TPR and DBP and a shortening of QS2c. (Figure 2) How-
ever, there was no significant difference in the haemody-
namic responses to oral glucose loading between T-allele
carriers and non-carriers (Table 2, Figure 2).
Discussion
The epidemiologic associations among essential hyper-
tension, obesity and non-insulin-dependent diabetes
mellitus are well recognized. To date, an underlying com-
mon pathophysiological mechanism has not been identi-
Changes in glucose and insulin following oral glucose load Figure 1
Changes in glucose and insulin following oral glucose load. 
Glucose and insulin responses to glucose loading are dis-
played as function of time. All values are mean ± SEM.
Changes in glucose and insulin following oral glucose load Figure 2
Changes in glucose and insulin following oral glucose load. 
Responses of cardiac output and total peripheral resistance 
to glucose loading are displayed as function of time. All values 
are mean ± SEM.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/7
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fied [32]. The rationale of the present study was based on
the assumption that the C825T polymorphism in the gene
GNB3, which is associated with obesity and hypertension
[2,8], may be also associated with an impaired glucose tol-
erance in young, healthy subjects.
In this study, we did not find that subjects carrying the T-
allele exhibited an altered response of any metabolic or
haemodynamic parameter to oral glucose load. Several
indices of insulin sensitivity were evaluated, including
fasting insulin levels, maximal and total insulin secretion
and the insulinogenic index that estimates early insulin
secretion. None of these indices was significantly influ-
enced by the presence of the 825T-allele. Hence, these
data do not support the hypothesis that the C825T poly-
morphism serves as an early genetic marker of an
impaired glucose tolerance in young, normotensive men.
There is conflicting evidence in the literature whether the
GNB3 gene may serve as a candidate gene for diabetes
mellitus type 2. In a case-control study (n = 1284),
Rosskopf et al. found a significant association between the
825T-allele and type 2 diabetes [33]. In contrast, Beige et
al found no increased frequency of this polymorphism in
a cohort of 1008 diabetic patients [34]. Moreover, there
was no association between the 825T-allele with diabetic
complications, including nephropathy, retinopathy and
neuropathy [34,35]. The results of the present study are
consistent with a recent report from Saller et al., who did
not find differences between TC and CC genotypes with
regard to time-courses for glucose and insulin concentra-
tions after an oral glucose tolerance test [36]. As in the
study by Saller et al., our study does not provide any evi-
dence for a pathogenetic link between the C825T poly-
morphism and impaired glucose tolerance.
In light of the extensive use of association studies, identi-
fying and characterizing physiological relationships is
needed to validate the potential relevance of gene poly-
morphisms [37]. This is the first study elucidating a poten-
tial pathophysiological mechanism between the 825T-
allele and hemodynamic changes following oral glucose
loading.
Glucose loading produced marked haemodynamic
changes. Although there was no statistical significance, the
Table 2: Changes in glucose, insulin and haemodynamic parameters following an oral glucose load. Responses to glucose loading were 
quantified either as the maximum response during the 120 minutes observation period, as the area under the response profile (AUC) 
from 15 to 120 minute (comp. Figure 1, 2) or as insulinogenic index.
Max response CC CT/TT P-value 95% CI
Blood glucose [mg dl-1] 58.6 ± 6.6 57.0 ± 5.3 0.849 -15.7/18.9
Serum insulin [µU dl-1] 95.9 ± 16.9 118.3 ± 27.1 0.510 -92.4/47.4
Heart rate [per min] 8.7 ± 1.4 9.0 ± 0.7 0.834 -3.4/2.7
Systolic blood pressure [mm Hg] 6.5 ± 1.0 8.3 ± 0.8 0.173 -4.5/0.9
Diastolic blood pressure [mm Hg] -4.2 ± 1.3 -3.8 ± 0.9 0.793 -3.6/2.8
Stroke volume [ml] 15.2 ± 0.8 21.0 ± 3.0 0.090 -12.7/1.0
Cardiac output [l min-1] 1.2 ± 0.2 2.0 ± 0.2 0.071 -1.3/-0.2
Total peripheral resistance [dyne sec cm-5] -300 ± 64.4 -289 ± 33.8 0.880 -159/137
Total electromechanical systole [ms] -16.3 ± 2.2 -17.1 ± 1.8 0.772 -5.0/6.7
AUC response CC CT/TT P-value 95% CI
Blood glucose [mg dl-1] 3184 ± 740 3136 ± 452 0.954 -1694/1792
Serum insulin [µU dl-1] 7388 ± 1425 7223 ± 1219 0.930 -3722/4052
Heart rate [per min] 425 ± 122 582 ± 71 0.259 -439/125
Systolic blood pressure [mm Hg] 521 ± 90 752 ± 73 0.058 -472/8
Diastolic blood pressure [mm Hg] 367 ± 116 302 ± 87 0.346 -435/159
Stroke volume [ml] 836 ± 195 764 ± 202 0.800 -517/662
Cardiac output [l min-1] 88 ± 19 104 ± 12 0.478 -63/31
Total peripheral resistance [dyne sec cm-5] 1383 ± 122.4 1216 ± 77.3 0.273 -21877/6536
Total electromechanical systole [ms] -1242 ± 259 -1499 ± 172 0.408 -376/888
CC CT/TT P-value 95% CI
Insulinogenic index 2.43 ± 0.87 1.96 ± 0.49 0.628 -2.468/1.525
Data are mean ± SEM. P-values determined in a two-tailed unpaired t-test between CC-genotypes (data column 1) and combined CT/TT-genotypes 
(data column 2). 95% CI: 95% confidence interval.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/7
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overall change (AUC) in systolic blood pressure tended to
be larger in carriers of the T-allele (p = 0.058). Observed
increases in stroke volume, cardiac output, heart rate and
shortening of the QS2c demonstrate a strong activation of
the sympathetic nervous system [38]. Insulin is a centrally
acting hormone and is known to stimulate sympathetic
nerve activity [39]. Given that the rises of these haemody-
namic parameters were closely timed to the insulin
increase further suggests that insulin induced activation of
the sympathetic nervous system is responsible for the
observed haemodynamic changes. Consistent with previ-
ous reports [40], we also observed a fall in total peripheral
resistance and diastolic blood pressure that may be
attributed to splanchnic vasodilatation during intestinal
resorption [41]. Together, the pronounced haemody-
namic changes following oral glucose loading illustrated
the tight coregulation of the metabolic and cardiovascular
systems.
Age is a major determinant of genotype penetrance and
phenotype expression in many inherited disorders includ-
ing cystic kidney disease and cancer [42,43]. Similarly,
impaired glucose tolerance occurs more frequently with
advancing age [44], and an association between the GNB3
825T-allele and reduced insulin sensitivity in middle-aged
men with abdominal fat distribution has been recently
described [45]. The subjects in our study ranged from 21
to 32 years of age. Hence, it is unclear whether or not our
results can be extended to older individuals, i.e. whether
the 825T locus may modify glucose handling in the eld-
erly. However, a homogeneous study population is
advantageous, particularly when anticipated differences
may be small. It is possible that the small population size
used may be a potential limitation in this study.
In this study we employed systolic time intervals and
impedance cardiography. Even though these techniques
are less frequently used than other modern techniques
such as echo-doppler calculations, they provide accurate
and reproducible measures of systemic hemodynamics. In
particular systolic time intervals are highly reproducible as
determined by the coefficient of correlation [18].
In conclusion, these findings do not support the hypoth-
esis that the GNB3 825T-allele is associated with impaired
glucose tolerance, or serves as an early genetic marker of
impaired glucose tolerance in young, normotensive men.
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